News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SAGE Therapeutics' Refractory Status Epilepticus Program Demonstrates Efficacy in First-in-Man Experience; Case Study to be Highlighted at International SE Meeting



4/4/2013 11:51:43 AM

CAMBRIDGE, Mass. & SALZBURG, Austria--(BUSINESS WIRE)--SAGE Therapeutics, a neuroscience product focused company creating novel medicines to treat important central nervous system (CNS) disorders, today announced that SGE-102, the company’s proprietary positive GABAA receptor allosteric modulator for status epilepticus (SE), will be highlighted at The 4th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures, being held April 4-6, 2013 in Salzburg, Austria. Data from the company’s preclinical SGE-102 program, a case study on the first-in-man treatment of intravenous (IV) SGE-102 in refractory SE and an overview of SAGE’s planned Phase 1/2 clinical trial of SGE-102 in patients with refractory SE will all be presented at the conference. SE is an acute, life-threatening form of epilepsy or seizures in which a patient experiences continuous or rapidly repeating seizures and occurs in approximately 200,000 U.S. patients each year.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES